Uroplakin II outperforms uroplakin III in diagnostically challenging settings

Steven C. Smith, Sambit K. Mohanty, Lakshmi P. Kunju, Elena Chang, Fai Chung, Jason C. Carvalho, Gladel P. Paner, Donna E. Hansel, Daniel J. Luthringer, Mariza N. de Peralta-Ventrurina, Mahul Amin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Aims: We performed a head-to-head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. Methods and results: We immunostained high-grade bladder neck carcinomas (n = 35), high-grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque-like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P < 0.001), including improved sensitivity (68% versus 23%) and equal specificity (both 100%) for UC (P = 0.006). Among UC metastases, UP2 staining showed greater intensity and proportion (both P < 0.001) with higher sensitivity (73% versus 37%, respectively, P = 0.001). Of 88 additional cases tested, no non-urothelial cases stained for either UP. Conclusions: The UP2 antibody outperforms the UP3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC.

Original languageEnglish (US)
Pages (from-to)132-138
Number of pages7
JournalHistopathology
Volume65
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Uroplakin II
Uroplakin III
Carcinoma
Staining and Labeling
Antibodies
Urinary Bladder
Neoplasm Metastasis
Prostate

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Cite this

Smith, S. C., Mohanty, S. K., Kunju, L. P., Chang, E., Chung, F., Carvalho, J. C., ... Amin, M. (2014). Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology, 65(1), 132-138. https://doi.org/10.1111/his.12360

Uroplakin II outperforms uroplakin III in diagnostically challenging settings. / Smith, Steven C.; Mohanty, Sambit K.; Kunju, Lakshmi P.; Chang, Elena; Chung, Fai; Carvalho, Jason C.; Paner, Gladel P.; Hansel, Donna E.; Luthringer, Daniel J.; de Peralta-Ventrurina, Mariza N.; Amin, Mahul.

In: Histopathology, Vol. 65, No. 1, 01.01.2014, p. 132-138.

Research output: Contribution to journalArticle

Smith, SC, Mohanty, SK, Kunju, LP, Chang, E, Chung, F, Carvalho, JC, Paner, GP, Hansel, DE, Luthringer, DJ, de Peralta-Ventrurina, MN & Amin, M 2014, 'Uroplakin II outperforms uroplakin III in diagnostically challenging settings', Histopathology, vol. 65, no. 1, pp. 132-138. https://doi.org/10.1111/his.12360
Smith SC, Mohanty SK, Kunju LP, Chang E, Chung F, Carvalho JC et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology. 2014 Jan 1;65(1):132-138. https://doi.org/10.1111/his.12360
Smith, Steven C. ; Mohanty, Sambit K. ; Kunju, Lakshmi P. ; Chang, Elena ; Chung, Fai ; Carvalho, Jason C. ; Paner, Gladel P. ; Hansel, Donna E. ; Luthringer, Daniel J. ; de Peralta-Ventrurina, Mariza N. ; Amin, Mahul. / Uroplakin II outperforms uroplakin III in diagnostically challenging settings. In: Histopathology. 2014 ; Vol. 65, No. 1. pp. 132-138.
@article{8d46379e9833450dbe24bacc4a9216ee,
title = "Uroplakin II outperforms uroplakin III in diagnostically challenging settings",
abstract = "Aims: We performed a head-to-head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. Methods and results: We immunostained high-grade bladder neck carcinomas (n = 35), high-grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque-like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63{\%} versus 19{\%}) and similar specificity (95{\%} versus 100{\%}) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P < 0.001), including improved sensitivity (68{\%} versus 23{\%}) and equal specificity (both 100{\%}) for UC (P = 0.006). Among UC metastases, UP2 staining showed greater intensity and proportion (both P < 0.001) with higher sensitivity (73{\%} versus 37{\%}, respectively, P = 0.001). Of 88 additional cases tested, no non-urothelial cases stained for either UP. Conclusions: The UP2 antibody outperforms the UP3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC.",
author = "Smith, {Steven C.} and Mohanty, {Sambit K.} and Kunju, {Lakshmi P.} and Elena Chang and Fai Chung and Carvalho, {Jason C.} and Paner, {Gladel P.} and Hansel, {Donna E.} and Luthringer, {Daniel J.} and {de Peralta-Ventrurina}, {Mariza N.} and Mahul Amin",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/his.12360",
language = "English (US)",
volume = "65",
pages = "132--138",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Uroplakin II outperforms uroplakin III in diagnostically challenging settings

AU - Smith, Steven C.

AU - Mohanty, Sambit K.

AU - Kunju, Lakshmi P.

AU - Chang, Elena

AU - Chung, Fai

AU - Carvalho, Jason C.

AU - Paner, Gladel P.

AU - Hansel, Donna E.

AU - Luthringer, Daniel J.

AU - de Peralta-Ventrurina, Mariza N.

AU - Amin, Mahul

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims: We performed a head-to-head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. Methods and results: We immunostained high-grade bladder neck carcinomas (n = 35), high-grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque-like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P < 0.001), including improved sensitivity (68% versus 23%) and equal specificity (both 100%) for UC (P = 0.006). Among UC metastases, UP2 staining showed greater intensity and proportion (both P < 0.001) with higher sensitivity (73% versus 37%, respectively, P = 0.001). Of 88 additional cases tested, no non-urothelial cases stained for either UP. Conclusions: The UP2 antibody outperforms the UP3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC.

AB - Aims: We performed a head-to-head comparison of an antibody against uroplakin III (UP3) and a new uroplakin II (UP2) antibody that remains untested in diagnostically challenging settings. Methods and results: We immunostained high-grade bladder neck carcinomas (n = 35), high-grade upper tract urothelial carcinomas (UC) and renal carcinomas (n = 85), metastases of UC (n = 30) and a multicancer tissue microarray (n = 88) for UP3 and UP2, and scored staining intensity and proportion. UP3 showed membranous plaque-like expression, while UP2 staining showed both membranous and cytoplasmic positivity. Significantly greater intensity (P = 0.003) and proportion (P = 0.03) of staining was noted for UP2 among bladder neck lesions, with UP2 staining showing greater sensitivity (63% versus 19%) and similar specificity (95% versus 100%) for UC over prostate carcinoma (P = 0.02). Among upper tract lesions, UP2 staining showed greater intensity and proportion than UP3 (both P < 0.001), including improved sensitivity (68% versus 23%) and equal specificity (both 100%) for UC (P = 0.006). Among UC metastases, UP2 staining showed greater intensity and proportion (both P < 0.001) with higher sensitivity (73% versus 37%, respectively, P = 0.001). Of 88 additional cases tested, no non-urothelial cases stained for either UP. Conclusions: The UP2 antibody outperforms the UP3 antibody, including in diagnostically challenging settings, and is a useful addition to the armamentarium of biomarkers for UC.

UR - http://www.scopus.com/inward/record.url?scp=84902110632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902110632&partnerID=8YFLogxK

U2 - 10.1111/his.12360

DO - 10.1111/his.12360

M3 - Article

VL - 65

SP - 132

EP - 138

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -